ArticleTranslational cancer research2025
Prognostic implications of a programmed cell death-related long non-coding RNA signature and its relevance to immune features in esophageal carcinoma.
Article in Translational cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Esophageal carcinoma (ESCA) is a highly lethal malignancy with poor prognosis and limited treatment options. The identification of effective prognostic biomarkers and therapeutic targets remains an important goal in improving outcomes for patients with ESCA. While the involvement of programmed cell death (PCD) mechanisms in cancer remains underexplored, they are thought to influence some aspects of tumor biology. The purpose of this study was to construct a prognostic signature derived from PCD-related long non-coding RNAs (lncRNAs) in ESCA. Methods: Transcriptome and clinical data from ESCA patients were sourced from The Cancer Genome Atlas (TCGA) database. Candidate lncRNAs associated with PCD and patient prognosis were identified and subjected to univariate, least absolute shrinkage and selection operator (LASSO), and multivariate Cox regression to build a prognostic signature. The signature's predictive performance was validated internally. To explore possible mechanisms underlying risk stratification, we employed multiple approaches, including weighted gene co-expression network analysis (WGCNA), gene set enrichment analysis (GSEA), and assessment of immune cell infiltration patterns. Results: Eight PCD-related lncRNAs (AC109347.1, BLACE, AP001527.2, AP001001.1, LINC00402, AC087289.5, FAM83C-AS1, and AL132655.2) were screened and incorporated into the prognostic signature. The signature appeared capable of distinguishing between high- and low-risk groups with distinct survival outcomes. Downregulation of immune-related pathways was observed in high-risk patients based on WGCNA and GSEA analyses. Immune cell infiltration and immune scoring metrics were comparatively lower in high-risk individuals. Based on drug response predictions, we identified potential agents that could be preferentially effective in high-risk ESCA patients. Conclusions: In conclusion, the PCD-related lncRNAs signature constructed in this study may contribute to prognosis assessment in ESCA and offers preliminary indications of immune involvement worthy of further investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.